Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Sarcoma
>>
CD Protein Inhibitors
>>
Phase 1
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
1
2
3
4
5
6
7
8
9
10
Omblastys
(131I-omburtamab) / Y-mAbs Therap
SCRI-CARB7H3(s)x19
/ Seattle Children's Hospital
sasanlimab
(PF-06801591) / Pfizer
CDX-1140
/ Celldex
Campath
(alemtuzumab) / Sanofi
LAE005
/ Laekna Therap
MK-4830
/ Merck (MSD)
NY-ESO-1 TCR-T cell therapy
/ Gilead
Rituxan Hycela
(rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Truxima
(rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
emactuzumab
(RG7155) / SynOx Therap
enoblituzumab
(MGA271) / MacroGenics
magrolimab
(ONO-7913) / Ono Pharma
mupadolimab
(CPI-006) / Corvus Pharma
orlotamab
(MGD009) / MacroGenics
pidilizumab
(CT-011) / CureTech
pradusinstobart
(LVGN3616) / Lyvgen
rhIL-15
/ National Cancer Institute
tidutamab
(XmAb18087) / Xencor
urelumab
(BMS-663513) / BMS, Ono Pharma
volrustomig
(MEDI5752) / AstraZeneca
